Comparative Pharmacology
Head-to-head clinical analysis: CARDIOQUIN versus TIKOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOQUIN versus TIKOSYN.
CARDIOQUIN vs TIKOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
10 hours (terminal) in patients with normal renal function; prolonged to up to 42 hours in severe renal impairment; clinically relevant for dosing interval adjustment.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Renal: 80% as unchanged drug; biliary/fecal: 20% (metabolites and minor parent drug).
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent